Sarah Kang1, Allen Brinker2, S Christopher Jones2, Lara Dimick-Santos3, Mark I Avigan2. 1. Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA. sarah.kang@fda.hhs.gov. 2. Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA. 3. Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Abstract
INTRODUCTION: Ulipristal acetate (ulipristal) is a selective progesterone receptor modulator that has been marketed for daily use in Europe and Canada to reduce symptoms caused by uterine fibroids. Long-term use of some other members of this class of 19-norprogesterone-derived agents has been associated with idiosyncratic hepatotoxicity. OBJECTIVE: We analyzed postmarketing reports of suspected drug-induced liver injury associated with the daily use of 5 mg of ulipristal to treat symptoms of uterine fibroids. METHODS: We searched for reports of serious liver injury associated with ulipristal, submitted to the US Food and Drug Administration through 31 January, 2020. Cases of liver injury temporally associated with long-term ulipristal exposure that reported combined increases of serum aminotransferases and bilirubin were individually assessed using a five-tier categorical scale of likelihood for a causal association with the drug by individuals with expertise in drug-induced liver injury evaluation. Individual cases that did not culminate in liver failure, death, or liver transplantation were also assessed for their causal association with ulipristal by the Roussel Uclaf Causality Assessment Method. RESULTS: We identified nine non-US cases that met the criteria for inclusion in our search for cases of serious liver injury associated with ulipristal. Five cases reported clinical outcomes of liver transplantation and/or death and all were assessed to have a probable causal association with ulipristal acetate. Evaluation of the other four cases reporting resolution of liver injury after treatment discontinuation revealed a possible or probable causal relationship with ulipristal. CONCLUSIONS: We identified postmarketing cases of serious acute drug-induced liver injury causally associated with ulipristal used to treat uterine fibroids, some with outcomes of liver transplant and/or death. The presence of common structural features identified with certain selective progesterone receptor modulators in the treatment of chronic conditions may indicate a liability for idiosyncratic drug-induced liver injury.
INTRODUCTION:Ulipristal acetate (ulipristal) is a selective progesterone receptor modulator that has been marketed for daily use in Europe and Canada to reduce symptoms caused by uterine fibroids. Long-term use of some other members of this class of 19-norprogesterone-derived agents has been associated with idiosyncratic hepatotoxicity. OBJECTIVE: We analyzed postmarketing reports of suspected drug-induced liver injury associated with the daily use of 5 mg of ulipristal to treat symptoms of uterine fibroids. METHODS: We searched for reports of serious liver injury associated with ulipristal, submitted to the US Food and Drug Administration through 31 January, 2020. Cases of liver injury temporally associated with long-term ulipristal exposure that reported combined increases of serum aminotransferases and bilirubin were individually assessed using a five-tier categorical scale of likelihood for a causal association with the drug by individuals with expertise in drug-induced liver injury evaluation. Individual cases that did not culminate in liver failure, death, or liver transplantation were also assessed for their causal association with ulipristal by the Roussel Uclaf Causality Assessment Method. RESULTS: We identified nine non-US cases that met the criteria for inclusion in our search for cases of serious liver injury associated with ulipristal. Five cases reported clinical outcomes of liver transplantation and/or death and all were assessed to have a probable causal association with ulipristal acetate. Evaluation of the other four cases reporting resolution of liver injury after treatment discontinuation revealed a possible or probable causal relationship with ulipristal. CONCLUSIONS: We identified postmarketing cases of serious acute drug-induced liver injury causally associated with ulipristal used to treat uterine fibroids, some with outcomes of liver transplant and/or death. The presence of common structural features identified with certain selective progesterone receptor modulators in the treatment of chronic conditions may indicate a liability for idiosyncratic drug-induced liver injury.
Authors: Jacques Donnez; Francisco Vázquez; Janusz Tomaszewski; Kazem Nouri; Philippe Bouchard; Bart C J M Fauser; David H Barlow; Santiago Palacios; Olivier Donnez; Elke Bestel; Ian Osterloh; Ernest Loumaye Journal: Fertil Steril Date: 2014-03-12 Impact factor: 7.329
Authors: Ahmed M Soliman; Mary Kay Margolis; Jane Castelli-Haley; Mahesh J Fuldeore; Charlotte D Owens; Karin S Coyne Journal: Curr Med Res Opin Date: 2017-09-12 Impact factor: 2.580
Authors: Jacques Donnez; Tetyana F Tatarchuk; Philippe Bouchard; Lucian Puscasiu; Nataliya F Zakharenko; Tatiana Ivanova; Gyula Ugocsai; Michal Mara; Manju P Jilla; Elke Bestel; Paul Terrill; Ian Osterloh; Ernest Loumaye Journal: N Engl J Med Date: 2012-02-02 Impact factor: 91.245
Authors: Jacques Donnez; Janusz Tomaszewski; Francisco Vázquez; Philippe Bouchard; Boguslav Lemieszczuk; Francesco Baró; Kazem Nouri; Luigi Selvaggi; Krzysztof Sodowski; Elke Bestel; Paul Terrill; Ian Osterloh; Ernest Loumaye Journal: N Engl J Med Date: 2012-02-02 Impact factor: 91.245